Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
David R. Lynch, MD, PhD

David R. Lynch, MD, PhD Non-Penn Medicine Provider

Professor of Neurology
Professor of Neurology in Pediatrics

Dr. Lynch is employed by the Children's Hospital of Philadelphia.

About Dr. David R. Lynch

Recognized by Best Doctors in America 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014

Recognized in Philadelphia Magazine's May 2002 Top Docs issue

Clinical Specialties

Specialty:

  • Neurology

Programs & Centers:

Board Certification:

  • Neurology, 1993

Clinical Expertise:

  • Ataxia
  • Neurogenetics
  • Parkinson's Disease

Practice Locations and Appointments

  • Penn Neurology

    Penn Neuroscience Center Perelman Center for Advanced Medicine, South Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Academy of Neurology, National American Neurological Association, International Australian Medical Research Council, International Cooperative Ataxia Group (CAG), National French Government Scientific Review, International Friedreich Ataxia Research Alliance, National Government, Czech Republic, International MDA, National National Ataxia Foundation, National NeuroNext, International NIH RAID Program, National NIH, National NINDS Committee on Common Data Elements, International Society for Neuroscience, National

Hospital Affiliation

Dr. Lynch is employed by the Children's Hospital of Philadelphia.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

RESEARCH INTERESTS
NMDA receptors

KEY WORDS:
glutamate, receptor

RESEARCH TECHNIQUES
Molecular biology

RESEARCH SUMMARY
Excitotoxicity is a unique pathophysiological mechanism which is involved in cerebral ischemia, secondary damage in neuronal trauma, and neuronal damage from prolonged seizures. The deleterious effects from excitotoxicity result from calcium entry through a specific glutamate receptor, the N-methyl D-aspartate (NMDA) receptor. NMDA receptor antagonists act both as neuroprotective agents against excitotoxicity and as anticonvulsants in animals, but human clinical trials with the most potent agents have been complicated by side effects including psychosis. Much evidence indicates the presence of multiple types of NMDA receptors in the brain, and evidence from our laboratory suggests that different subtypes play different roles in physiological and excitotoxic processes. If one could develop therapeutic agents which are selective for the subtypes involved in excitotoxicity, one could more readily utilize NMDA receptor antagonists for treatment of human diseases.

We use a systematic approach to examine the subtype specific physiological and pharmacological properties of NMDA receptors. NMDA receptors are created in tissue culture expression systems, and their properties are studied biochemically, pharmacologically and physiologically to correlate receptor properties in these systems with such properties in vivo. We have previously shown that different NMDA receptor subtypes have distinct pharmacologies and produce different changes in intracellular calcium. In the near future we will extend these examinations of subtype specific properties to include the modulation of other intracellular messengers such as nitric oxide and examine the effect of such properties on excitotoxicity. Combined with our studies on the pharmacological specificity of NMDA receptor subtypes, this will facilitate the development of therapeutic agents directed to those NMDA receptors which play crucial roles in excitotoxicity.

Selected Publications:

Yang, Y.,Zhang, L.,Lynch, D. R., Lukas, T. Ahmeti, K., Sleiman, P.M.A., Ryan, E., Schadt, K. A., Newman, J. H., Siddique, N., Siddique, T.: Compound heterozygote mutations in SPG7 in a family with adult-onset primary lateral sclerosis Neurology Genetics 2 (2): e60,2016.

Galea, C. A., Huq, A., Lockhart, P.J., Tai, G. Corben, L.A., Yiu, E. M., Gurrin, L. C., Lynch, D. R., Gelbard, S., Durr, A., Pousset11, F., Parkinson, M., Labrum, R., Giunti, P., Perlman, S. L., Delatycki, M. B., and Evans-Galea, M. V.: Compound heterozygous FXN mutations and clinical outcome in Friedreich ataxia Annals of Neurology 79 (3): 485-95.,2016.

Lin, H.,Jacobi, A.A., Anderson, S.A, Lynch, D.R.: Postsynaptic D-serine modulates serine racemase/PSD95 signaling and glutamatergic synapse formation in an autocrine manner Frontiers in Cellular Neuroscience 10 (34): doi: 10.3389/fncel.2016.00034.,2016.

Shinnick, J. , Isaacs, C. J., Vivaldi, S., Schadt, K. A., Lynch, D. R.: Friedreich Ataxia and Nephrotic Syndrome: A Series of Two Patients BMC Neurology 16 (1): 3,2016.

Bhalla,A. D., Jamayran, A.K., Li, Y., Lynch, D. R., Napierala, M.: Deep sequencing of mitochondrial genomes reveals increased mutation load in Friedreich’s Ataxia Annals of Clinical and Translational Neurology : 2016.

Li, Y.,Polak, U., Clark, A.D., Bhalla, A.,Chen, Y.-Y., Li, J, Farmer, J., Seyer, L., Lynch, D., Butler, J.S., M. Napierala: Establishing and maintenance of primary fibroblast repositories for rare diseases – Friedreich’s ataxia example Biopreservation and Biobanking : 2016.

Isaacs, C.J., Brigatti, K.W., Kucheruk, O., Ratcliffe, S., Sciascia, T., McCormack, S. E., Willi, S.W., Lynch, D.R.: Effects of Genetic Severity on Glucose Homeostasis in Friedreich Ataxia Muscle and Nerve : 2016.

Shinnick, J.E., Schadt, K., Strawser, C., Wilcox, N., Perlman, S.L., Wilmot, G.R., Gomez, C.M., Mathews, K.D., Yoon, G., Zesiewicz, T., Hoyle,, C., Subramony, S.H., Yiu, E., Delatycki, M.B., Brocht, A.F. Farmer, J.M., Lynch, D.R.: Co-Morbid Medical Conditions in Friedreich Ataxia: Association with Inflammatory Bowel Disease and Growth Hormone Deficiency Journal of Child Neurology : 2016.

Li, Y. Lu, Y., Polak, U., Lin, K., Shen,J.,Farmer, J. Seyer, L., Bhalla1, A.D, Rozwadowska, N., Lynch, D.R.,Butler, J. S., Napierala, M: Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus Human Molecular Genetics 24 (24): 6932-43,2015.

Lazaropoulos, M. Dong, Y., Clark,E.,Greeley, N. R.,Seyer, L.A., Brigatti,K. W., Christie, C., Perlman, S. L., Wilmot, G.R.,. Gomez, C. M. Mathews, K. D.,Yoon, G., Zesiewicz, T., Hoyle, C.,. Subramony, S.H., Brocht, A. F., Farmer, J. M., Wilson, R. B., Deutsch, E. C., Lynch, D. R.: Frataxin levels in peripheral tissue in Friedreich Ataxia Annals of Clinical and Translational Neurology 2 (8): 831-42.,2015.

Academic Contact Info

502 Abramson Center
Children's Hospital of Philadelphia

Philadelphia, PA 19104
Phone: (215) 590-2242
Fax: (215) 590-3779
Patient appointments: 800-789-PENN (7366)

Related Links